JPWO2020031936A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020031936A5
JPWO2020031936A5 JP2020535747A JP2020535747A JPWO2020031936A5 JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5 JP 2020535747 A JP2020535747 A JP 2020535747A JP 2020535747 A JP2020535747 A JP 2020535747A JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
amino acid
drug conjugate
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020535747A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458981B2 (ja
JPWO2020031936A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/030635 external-priority patent/WO2020031936A1/ja
Publication of JPWO2020031936A1 publication Critical patent/JPWO2020031936A1/ja
Publication of JPWO2020031936A5 publication Critical patent/JPWO2020031936A5/ja
Priority to JP2024043043A priority Critical patent/JP7892713B2/ja
Application granted granted Critical
Publication of JP7458981B2 publication Critical patent/JP7458981B2/ja
Priority to JP2024158824A priority patent/JP7900454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020535747A 2018-08-06 2019-08-05 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ Active JP7458981B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024043043A JP7892713B2 (ja) 2018-08-06 2024-03-19 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2024158824A JP7900454B2 (ja) 2018-08-06 2024-09-13 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018147582 2018-08-06
JP2018147582 2018-08-06
PCT/JP2019/030635 WO2020031936A1 (ja) 2018-08-06 2019-08-05 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024043043A Division JP7892713B2 (ja) 2018-08-06 2024-03-19 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JPWO2020031936A1 JPWO2020031936A1 (ja) 2021-08-10
JPWO2020031936A5 true JPWO2020031936A5 (cg-RX-API-DMAC7.html) 2022-08-15
JP7458981B2 JP7458981B2 (ja) 2024-04-01

Family

ID=69414755

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020535747A Active JP7458981B2 (ja) 2018-08-06 2019-08-05 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2024043043A Active JP7892713B2 (ja) 2018-08-06 2024-03-19 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2024158824A Active JP7900454B2 (ja) 2018-08-06 2024-09-13 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024043043A Active JP7892713B2 (ja) 2018-08-06 2024-03-19 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2024158824A Active JP7900454B2 (ja) 2018-08-06 2024-09-13 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ

Country Status (11)

Country Link
US (2) US12497465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3834843A4 (cg-RX-API-DMAC7.html)
JP (3) JP7458981B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210042120A (cg-RX-API-DMAC7.html)
CN (1) CN112512587A (cg-RX-API-DMAC7.html)
AU (2) AU2019320336B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001750A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108754A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190471A1 (cg-RX-API-DMAC7.html)
TW (1) TW202019487A (cg-RX-API-DMAC7.html)
WO (1) WO2020031936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250004902A (ko) * 2017-08-23 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
BR112021001750A2 (pt) * 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica
IL288485B2 (en) * 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
JPWO2021200131A1 (cg-RX-API-DMAC7.html) * 2020-03-30 2021-10-07
US12605459B2 (en) 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
IL301921A (en) * 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药(苏州)股份有限公司 一种抗体偶联物中间体及其制备方法
US20240058463A1 (en) * 2020-12-18 2024-02-22 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
EP4393514A1 (en) * 2021-08-24 2024-07-03 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
US20240390512A1 (en) * 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
CN119255825A (zh) * 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
CN118955614B (zh) * 2022-07-05 2025-12-30 上海药明合联生物技术有限公司 偶联连接子
AU2024236246A1 (en) * 2023-03-14 2025-10-30 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor
JPWO2024204679A1 (cg-RX-API-DMAC7.html) * 2023-03-31 2024-10-03
WO2025002310A1 (zh) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2026128344A1 (en) * 2024-12-09 2026-06-18 Merck Sharp & Dohme Llc Combinations for the treatment of cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
AU2006262231B2 (en) 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CN103239455A (zh) 2012-12-24 2013-08-14 苏州大学 有协同治疗效果和高载药量的多组分纳米药物的制备方法
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
MX2017001946A (es) * 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
AU2016366677A1 (en) * 2015-12-09 2018-07-26 Nantcell, Inc. Compositions and methods for treatment of HER2 positive metastatic breast cancer
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112021001750A2 (pt) * 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica

Similar Documents

Publication Publication Date Title
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
JP2025041725A5 (cg-RX-API-DMAC7.html)
AU2019408811B2 (en) Saponin conjugated to epitope-binding proteins
JP7458981B2 (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP6328649B2 (ja) 薬物−タンパク質コンジュゲート
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP6473138B2 (ja) 癌、特に前立腺癌を標的とする合成抗体模倣化合物(SyAM)
JP2008546792A5 (cg-RX-API-DMAC7.html)
JP2020515578A5 (cg-RX-API-DMAC7.html)
JP2020524675A5 (cg-RX-API-DMAC7.html)
JP2013100314A5 (cg-RX-API-DMAC7.html)
JP2017528418A5 (cg-RX-API-DMAC7.html)
JP2018537975A5 (cg-RX-API-DMAC7.html)
JP2018509394A5 (cg-RX-API-DMAC7.html)
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2015500287A (ja) 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
JP2016511637A5 (cg-RX-API-DMAC7.html)
JP2012522512A5 (cg-RX-API-DMAC7.html)
EP3218414A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
JP2014508767A (ja) 改善されたリンケージを有するアマトキシン複合体
JPWO2020027100A5 (cg-RX-API-DMAC7.html)
JPWO2022102634A5 (cg-RX-API-DMAC7.html)
RU2018119683A (ru) Сайт-специфические конъюгаты антитела к her2 и лекарственного средства
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения